Perimenopause Global Prevalence and Trends

How Many Women Are Going Through Perimenopause Right Now?

The scale is large. The World Health Organization estimates that by 2025, approximately 1.1 billion women will be postmenopausal or in the menopausal transition, with roughly 47 million new cases of perimenopause occurring each year [1]. That figure will grow to an estimated 1.2 billion by 2030 as the global population ages.

These numbers reflect demographic arithmetic as much as biology. As life expectancy extends in low- and middle-income countries, a rising share of the female population reaches the perimenopausal years. In 2020, the United Nations Population Division estimated that women aged 45 to 54 numbered approximately 470 million globally, the age band that captures the bulk of perimenopausal experience [2].

Why Counting Is Harder Than It Sounds

Perimenopause is defined by menstrual cycle irregularity rather than a single biomarker. The STRAW+10 staging system, published in 2012 and endorsed by the Menopause Society (formerly NAMS), the American Society for Reproductive Medicine (ASRM), and the Endocrine Society, classifies early perimenopause as cycles varying by 7 or more days from baseline, and late perimenopause as 60-day or longer cycle gaps [3]. Because most national health registries record the final menstrual period (FMP) rather than onset of irregularity, surveillance data systematically undercount women currently in transition.

Population-Level Projections

A 2021 analysis in the journal Maturitas estimated that the number of women reaching natural menopause globally each year would exceed 25 million by 2025, up from about 21 million in 2000 [4]. The gap between that figure and the 47 million entering perimenopause each year reflects the multi-year duration of the transition itself.

Average Age of Onset: What the Data Show Across Populations

Most Western studies place the average onset of perimenopause between 45 and 47 years, with the final menstrual period arriving at a median of 51.4 years in U.S. Women [5]. The Study of Women's Health Across the Nation (SWAN), which followed 3,302 women across seven U.S. Sites from 1996 onward, remains the most detailed longitudinal dataset on this question.

SWAN Findings on Onset and Duration

SWAN data published in JAMA Internal Medicine showed that the median age at which women first experienced a 60-day amenorrhea interval was 47.5 years [6]. The late menopausal transition lasted a median of 3.8 years from that point to the FMP. When early perimenopause was included, total transition duration ranged from 1 to more than 13 years, with a median near 4 years for the combined early-plus-late stage. The Menopause Society states: "The menopausal transition, or perimenopause, begins with variation in menstrual cycle length and ends 12 months after the final menstrual period" [3].

Geographic and Ethnic Variation in Onset Age

Age at natural menopause varies by roughly 2 to 4 years across populations, and perimenopause onset tracks with it. A Lancet meta-analysis of data from 17 studies across Europe, North America, and Asia found that smoking, lower body mass index, and lower parity were independently associated with earlier transition onset [7]. Japanese women in population studies have reported a median FMP near age 50, slightly earlier than the U.S. Median, while some South Asian cohorts report a median closer to 44 years, though study ascertainment methods differ [8].

Symptom Burden: Prevalence Rates by Type and Population

Not every woman in perimenopause experiences disabling symptoms. But the proportion who do is substantial.

Vasomotor Symptoms

Hot flashes and night sweats, collectively called vasomotor symptoms (VMS), affect an estimated 40 to 80 percent of perimenopausal women in Western cohorts [9]. SWAN data showed that African American women reported the highest VMS frequency (45.6 percent at baseline), followed by Hispanic women (35.4 percent), White women (31.2 percent), Chinese American women (20.5 percent), and Japanese American women (17.6 percent) [10]. These differences persisted after adjustment for body mass index, smoking, and socioeconomic status, pointing to underlying biological and cultural factors.

The Freeman and Sherif analysis in Menopause (2007) found that VMS could begin up to 6 years before the FMP and persist 4 to 5 years after it in a meaningful subset of women. For Black women specifically, VMS duration was on average 10.1 years vs. 6.5 years for White women, per the SWAN follow-up data published in JAMA Internal Medicine in 2015 [11].

Sleep Disturbance

Self-reported sleep problems affect up to 62 percent of perimenopausal women, compared with 38 percent of premenopausal women, based on the 2007 National Sleep Foundation Women and Sleep poll and confirmed in SWAN ancillary analyses [12]. Polysomnographic studies show increased wake-after-sleep-onset (WASO) even after controlling for VMS, suggesting direct neuroendocrine effects on sleep architecture beyond the secondary disruption caused by night sweats.

Mood and Cognitive Symptoms

A meta-analysis of 11 prospective studies published in Menopause (2018) found that perimenopausal women had a 40 percent higher risk of depressive symptoms compared with premenopausal women (pooled relative risk 1.40, 95% CI 1.20 to 1.63) [13]. The Penn Ovarian Aging Study, which tracked 436 women over 8 years, showed that first onset of major depressive disorder was 2.5 times more likely in the perimenopausal period than in premenopausal years [14].

Racial and Ethnic Disparities in Perimenopause Experience

Disparities in perimenopause are not simply about symptom frequency. They extend to treatment access, time-to-diagnosis, and health outcomes downstream.

Access to Hormone Therapy

A 2020 JAMA Internal Medicine cross-sectional analysis of more than 200,000 U.S. Women found that African American and Hispanic women were significantly less likely to receive a prescription for menopausal hormone therapy (MHT) than White women, even after adjusting for contraindications and insurance status [15]. The adjusted odds ratio for MHT prescription was 0.54 (95% CI 0.48 to 0.61) for Black women relative to White women.

Socioeconomic Gradients

Lower educational attainment and household income are independently associated with earlier menopausal transition in multiple datasets. The British Women's Heart and Health Study found a 1.4-year earlier mean FMP in women in the lowest vs. Highest socioeconomic quintile [16]. Earlier transition is clinically relevant because it extends the years of estrogen deprivation before treatment is typically considered.

The HealthRX Perimenopause Disparity Framework

When reviewing a patient's symptom timeline, three axes shape both risk and treatment response in ways aggregate statistics obscure. First, self-reported race and ethnicity (given SWAN's documented VMS frequency differences). Second, years of education as a proxy for health literacy and ability to advocate for treatment. Third, current smoking status, which independently advances transition onset by approximately 1.5 years per the Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis [17]. Applying these three variables at intake helps clinicians stratify who needs earlier symptom screening rather than waiting for a patient to report distress.

How Perimenopause Duration Affects Long-Term Health Risks

The length of the perimenopausal transition matters beyond symptom burden because estrogen fluctuation during this window directly affects bone, cardiovascular, and metabolic health.

Bone Density Changes

Bone loss accelerates during the late menopausal transition. The SWAN bone density substudy showed that women lost an average of 1.8 to 2.3 percent of lumbar spine bone mineral density per year during the 2 years surrounding the FMP, compared with 0.1 percent per year in the premenopausal period [18]. Women who entered perimenopause early (before age 45) had cumulatively greater bone loss by age 60 than women with onset at 47 or later.

Cardiovascular Risk

The American Heart Association's 2020 scientific statement on menopause and cardiovascular disease notes that the perimenopausal transition is associated with adverse changes in LDL cholesterol, triglycerides, blood pressure, and visceral adiposity independent of chronological aging [19]. The statement specifies: "Women should be counseled that cardiovascular risk increases during and after the menopausal transition, and this risk may be modified by the timing and type of hormone therapy initiated."

Metabolic Changes

Insulin sensitivity declines during the late menopausal transition. A cross-sectional analysis from the SWAN Heart substudy found that women in late perimenopause had a 17 percent higher homeostatic model assessment for insulin resistance (HOMA-IR) score compared with premenopausal women matched for age and BMI [20].

Geographic Trends: Where Perimenopause Burden Is Growing Fastest

The fastest growth in the perimenopausal population is occurring in sub-Saharan Africa, South Asia, and Southeast Asia, where improved childhood survival and extended life expectancy are rapidly increasing the number of women surviving to midlife.

Low- and Middle-Income Countries

The WHO projects that by 2030, more than 1.2 billion women will be postmenopausal, with the majority of that population living in low- and middle-income countries [1]. These same countries have the least access to validated perimenopause symptom tools, specialist gynecology, and MHT. A systematic review in Climacteric (2019) identified only 31 population-based perimenopause studies from Africa, covering fewer than 8 percent of sub-Saharan African nations [21].

Asia-Pacific Region

Asia-Pacific accounts for the largest absolute perimenopausal population. A multicountry survey published in Maturitas (2010) sampled 4,869 women aged 40 to 60 across 11 Asia-Pacific countries and found that 55 percent reported at least one moderate-to-severe menopausal symptom, with somatic symptoms (joint pain, fatigue) more frequently reported as the primary complaint than VMS, a pattern distinct from Western cohorts [22].

High-Income Country Trends

In the United States, the perimenopausal-age cohort (45 to 54) numbered approximately 44 million women in 2023, based on U.S. Census Bureau estimates. That number is expected to remain near 42 to 44 million through 2035 as the last of the baby-boom generation ages through this window. In the UK, the Government's 2022 Women's Health Strategy cited perimenopause as one of three priority areas for NHS investment, estimating that 13 million British women are currently perimenopausal or postmenopausal [23].

Diagnostic Delays and Awareness Gaps

Awareness gaps directly translate into delayed care. A 2021 survey by the British Menopause Society of 1,000 perimenopausal women found that 43 percent visited their GP three or more times before receiving a perimenopause diagnosis, and 37 percent reported being initially offered antidepressants without a discussion of MHT [24].

The Symptom Attribution Problem

Because perimenopause symptoms such as mood changes, fatigue, and joint pain are nonspecific, clinicians and patients alike may attribute them to stress, depression, or thyroid dysfunction. The STRAW+10 criteria require no laboratory confirmation for staging the early menopausal transition; menstrual calendar data alone are sufficient [3]. However, a 2019 Menopause Society survey found that fewer than 30 percent of U.S. Primary care physicians used a standardized staging tool during annual wellness visits for women aged 40 to 55.

FSH Testing Limitations

Serum FSH is widely ordered but poorly suited to confirm perimenopause in women with intact ovarian function. The Endocrine Society's 2015 clinical practice guideline on menopause states that FSH concentrations "fluctuate substantially during the menopausal transition and cannot be used alone to confirm perimenopause or predict time to the final menstrual period" [25]. A single FSH >25 mIU/mL in a woman still having periods does not confirm perimenopause; serial measurements over 6 to 12 months are more informative.

Current Treatment Field and Gaps

Despite the scale of perimenopausal symptom burden, MHT remains underused globally.

MHT Utilization Data

U.S. MHT prescription rates fell sharply after the Women's Health Initiative (WHI) initial reports in 2002 and 2003 and have recovered only partially. A 2022 analysis in Menopause estimated that only 6 to 7 percent of U.S. Women currently eligible for MHT (symptomatic, no absolute contraindications) are receiving it [26]. In the UK, NHS prescription data showed a 38 percent increase in MHT prescriptions between 2019 and 2022, partly attributed to increased public awareness following media coverage, but absolute rates remain below estimated need [23].

Guideline Recommendations

The 2023 Menopause Society Position Statement specifies that MHT is the "most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, and has been shown to prevent bone loss and fracture" in appropriate candidates [27]. For women aged <60 years or within 10 years of menopause onset, the benefit-to-risk ratio for MHT is favorable in the absence of contraindications.

Non-hormonal options for women who cannot or choose not to use MHT include fezolinetant (Veozah), the first FDA-approved neurokinin-3 receptor antagonist for moderate-to-severe VMS. The key SKYLIGHT 1 and SKYLIGHT 2 trials (combined N=1,022) showed a 56 to 64 percent reduction in mean weekly moderate-to-severe hot flash frequency at 12 weeks compared with 28 to 35 percent for placebo [28].